| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Lene Jessen, Eric P Smith, Yvonne Ulrich-Lai, James P Herman, Randy J Seeley, Darleen Sandoval, David D'Alessi. Central Nervous System GLP-1 Receptors Regulate Islet Hormone Secretion and Glucose Homeostasis in Male Rats. Endocrinology. vol 158. issue 7. 2017-09-29. PMID:28430981. |
the glucagon-like peptide 1 (glp-1) system plays an important role in blood glucose regulation, in great part through coordinate control of insulin and glucagon secretion. |
2017-09-29 |
2023-08-13 |
rat |
| Lene Jessen, Eric P Smith, Yvonne Ulrich-Lai, James P Herman, Randy J Seeley, Darleen Sandoval, David D'Alessi. Central Nervous System GLP-1 Receptors Regulate Islet Hormone Secretion and Glucose Homeostasis in Male Rats. Endocrinology. vol 158. issue 7. 2017-09-29. PMID:28430981. |
administration of cns glp-1 increased fasting glucose, glucagon, corticosterone, and epinephrine and blunted insulin secretion in response to hyperglycemia. |
2017-09-29 |
2023-08-13 |
rat |
| Lene Jessen, Eric P Smith, Yvonne Ulrich-Lai, James P Herman, Randy J Seeley, Darleen Sandoval, David D'Alessi. Central Nervous System GLP-1 Receptors Regulate Islet Hormone Secretion and Glucose Homeostasis in Male Rats. Endocrinology. vol 158. issue 7. 2017-09-29. PMID:28430981. |
in contrast, blockade of brain glp-1r supports a role for cns glp-1 on glucose-stimulated insulin secretion and glucose control after a meal. |
2017-09-29 |
2023-08-13 |
rat |
| Yael Einbinder, Meital Ohana, Sydney Benchetrit, Tania Zehavi, Naomi Nacasch, Jacques Bernheim, Tali Zitman-Ga. Glucagon-like peptide-1 and vitamin D: anti-inflammatory response in diabetic kidney disease in db/db mice and in cultured endothelial cells. Diabetes/metabolism research and reviews. vol 32. issue 8. 2017-09-26. PMID:26991522. |
glucagon-like peptide-1 (glp-1) is a gut incretin hormone that stimulates insulin secretion and may affect the inflammatory pathways involved in diabetes mellitus. |
2017-09-26 |
2023-08-13 |
mouse |
| D Racca. Basal insulin treatment intensification in patients with type 2 diabetes mellitus: A comprehensive systematic review of current options. Diabetes & metabolism. vol 43. issue 2. 2017-09-26. PMID:28169086. |
the purpose of this systematic review was to examine the evidence supporting the use of the available add-on treatments [rapid-acting insulin (rai), glucagon-like peptide-1 receptor agonists (glp-1 ras), dipeptidyl peptidase (dpp)-4 inhibitors and sodium-glucose cotransporter-2 (sglt-2) inhibitors] to basal insulin. |
2017-09-26 |
2023-08-13 |
Not clear |
| Yi Zhang, Yaqin Ding, Xiangqin Zhong, Qing Guo, Hui Wang, Jingying Gao, Tao Bai, Lele Ren, Yangyan Guo, Xiangying Jiao, Yunfeng Li. Geniposide acutely stimulates insulin secretion in pancreatic β-cells by regulating GLP-1 receptor/cAMP signaling and ion channels. Molecular and cellular endocrinology. vol 430. 2017-09-25. PMID:27126219. |
geniposide acutely stimulates insulin secretion in pancreatic β-cells by regulating glp-1 receptor/camp signaling and ion channels. |
2017-09-25 |
2023-08-13 |
rat |
| Azazul Islam Chowdhury, Peter Bergste. GLP-1 analogue recovers impaired insulin secretion from human islets treated with palmitate via down-regulation of SOCS2. Molecular and cellular endocrinology. vol 439. 2017-09-25. PMID:27566229. |
glp-1 analogue recovers impaired insulin secretion from human islets treated with palmitate via down-regulation of socs2. |
2017-09-25 |
2023-08-13 |
human |
| Jens T Bukrinski, Pernille Sønderby, Filipa Antunes, Birgitte Andersen, Esben G W Schmidt, Günther H J Peters, Pernille Harri. Glucagon-like Peptide 1 Conjugated to Recombinant Human Serum Albumin Variants with Modified Neonatal Fc Receptor Binding Properties. Impact on Molecular Structure and Half-Life. Biochemistry. vol 56. issue 36. 2017-09-20. PMID:28799326. |
glucagon-like peptide 1 (glp-1) is a small incretin hormone stimulated by food intake, resulting in an amplification of the insulin response. |
2017-09-20 |
2023-08-13 |
human |
| Marie L Davies, David Q Pham, Scott R Dra. GLP1-RA Add-on Therapy in Patients with Type 2 Diabetes Currently on a Bolus Containing Insulin Regimen. Pharmacotherapy. vol 36. issue 8. 2017-09-19. PMID:27340935. |
adding glucagon-like peptide-1 receptor agonists (glp-1 ras) to basal insulin regimens has become a guideline-recommended treatment option for uncontrolled type 2 diabetes. |
2017-09-19 |
2023-08-13 |
human |
| Marie L Davies, David Q Pham, Scott R Dra. GLP1-RA Add-on Therapy in Patients with Type 2 Diabetes Currently on a Bolus Containing Insulin Regimen. Pharmacotherapy. vol 36. issue 8. 2017-09-19. PMID:27340935. |
however, limited data exist to support the use of glp-1 ras with insulin regimens, including bolus insulin in patients with type 2 diabetes. |
2017-09-19 |
2023-08-13 |
human |
| Marie L Davies, David Q Pham, Scott R Dra. GLP1-RA Add-on Therapy in Patients with Type 2 Diabetes Currently on a Bolus Containing Insulin Regimen. Pharmacotherapy. vol 36. issue 8. 2017-09-19. PMID:27340935. |
the primary objectives of this review were to identify if the combination of a glp-1 ra and an insulin regimen containing bolus insulin resulted in improvements in hba1c , weight loss, reduction in insulin doses, and to evaluate the side effect profile of this combination in terms of nausea and hypoglycemia risk. |
2017-09-19 |
2023-08-13 |
human |
| Marie L Davies, David Q Pham, Scott R Dra. GLP1-RA Add-on Therapy in Patients with Type 2 Diabetes Currently on a Bolus Containing Insulin Regimen. Pharmacotherapy. vol 36. issue 8. 2017-09-19. PMID:27340935. |
in some studies, a portion of patients were able to discontinue bolus insulin all together after initiation of a glp-1 ra. |
2017-09-19 |
2023-08-13 |
human |
| Marie L Davies, David Q Pham, Scott R Dra. GLP1-RA Add-on Therapy in Patients with Type 2 Diabetes Currently on a Bolus Containing Insulin Regimen. Pharmacotherapy. vol 36. issue 8. 2017-09-19. PMID:27340935. |
nausea was identified in 7-42% of participants using glp-1 ras with insulin. |
2017-09-19 |
2023-08-13 |
human |
| Marie L Davies, David Q Pham, Scott R Dra. GLP1-RA Add-on Therapy in Patients with Type 2 Diabetes Currently on a Bolus Containing Insulin Regimen. Pharmacotherapy. vol 36. issue 8. 2017-09-19. PMID:27340935. |
data support the use of glp-1 ras added to insulin regimens already containing bolus insulin for glycemic control, weight loss, and reduction or discontinuation of bolus insulin. |
2017-09-19 |
2023-08-13 |
human |
| Kira B Harris, Cassie L Bolan. Adjunctive Role of Glucagon-Like Peptide-1 Receptor Agonists in the Management of Type 1 Diabetes Mellitus. Pharmacotherapy. vol 36. issue 9. 2017-09-19. PMID:27485823. |
glucagon-like peptide-1 receptor agonists (glp-1 ras) are commonly used in combination with insulin to manage type 2 diabetes mellitus, and four agents are currently approved for this indication: exenatide, liraglutide, dulaglutide, and albiglutide. |
2017-09-19 |
2023-08-13 |
Not clear |
| Kira B Harris, Cassie L Bolan. Adjunctive Role of Glucagon-Like Peptide-1 Receptor Agonists in the Management of Type 1 Diabetes Mellitus. Pharmacotherapy. vol 36. issue 9. 2017-09-19. PMID:27485823. |
the distinctive properties of glp-1 ras-potential hemoglobin a1c (a1c) reduction, weight loss, potential to reduce insulin doses, and lower hypoglycemia risk-have made these agents potential treatment options for patients with type 1 diabetes mellitus (t1dm) as well. |
2017-09-19 |
2023-08-13 |
Not clear |
| Michael A Nauck, Juris J Meier, Matthew A Cavender, Mirna Abd El Aziz, Daniel J Drucke. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. Circulation. vol 136. issue 9. 2017-09-19. PMID:28847797. |
potentiation of glucagon-like peptide-1 (glp-1) action through selective glp-1 receptor (glp-1r) agonism or by prevention of enzymatic degradation by inhibition of dipeptidyl peptidase-4 (dpp-4) promotes glycemic reduction for the treatment of type 2 diabetes mellitus by glucose-dependent control of insulin and glucagon secretion. |
2017-09-19 |
2023-08-13 |
human |
| Ying Li, Xuemin Zheng, Xiulin Yi, Changxiao Liu, Dexin Kong, Jianning Zhang, Min Gon. Myricetin: a potent approach for the treatment of type 2 diabetes as a natural class B GPCR agonist. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. vol 31. issue 6. 2017-09-12. PMID:28270518. |
glp-1 is capable of regulating the blood glucose level by insulin secretion after administration of oral glucose. |
2017-09-12 |
2023-08-13 |
Not clear |
| Saad Elias, Sbeit Wisam, Arraf Luai, Barhoum Massad, Assy Nime. Lipotoxicity in Obesity: Benefit of Olive Oil. Advances in experimental medicine and biology. vol 960. 2017-09-12. PMID:28585218. |
olive oil rich diet decrease accumulation of triglyceride in the liver, improved postprandial triglyceride levels, improve glucose and glp-1 response in insulin resistant subjects, and up regulate glut-2 expression in the liver. |
2017-09-12 |
2023-08-13 |
human |
| Jens Juul Holst, Sten Madsba. Mechanisms of surgical control of type 2 diabetes: GLP-1 is key factor. Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery. vol 12. issue 6. 2017-09-11. PMID:27313194. |
indeed, human experiments with the glp-1 receptor antagonist, exendin 9-39, have shown that the improved insulin secretion, which is responsible for part of the antidiabetic effect of the operation, is reduced and or abolished after glp-1 receptor blockade. |
2017-09-11 |
2023-08-13 |
human |